Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vacation destinations in America - 2Could it be said that you are As yet Utilizing Old Tires? at These 6 Tire Brands
- 3Dolly Parton misses Dollywood event due to 'a few health challenges' after skipping honorary Oscars
- 4Yasser Abu Shabab's killing raises questions about Israel's militia strategy in Gaza
- 5Taco Bell debuts its Baja Blast pie, and the reactions may surprise you
- Supreme Court case about ‘crisis pregnancy centers’ highlights debate over truthful advertising standards
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- New dinosaur tracks in Italy illustrate herds moving in unison
- The most effective method to Pick the Right Material Organization: Fundamental Tips
- Father and son spending Christmas together after health scares
- Christmas 2025 skywatching guide: What you can see in the night sky on Dec. 25
- Strengthening through Wellness: Individual Preparation Achievement
- Protest inspired by 'Gen Z' movement draws few young people in Mexico and many government critics
- Famous Rough terrain Vehicles for 2024
